BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23064240)

  • 1. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.
    Mendell J; Noveck RJ; Shi M
    J Cardiovasc Pharmacol; 2012 Oct; 60(4):335-41. PubMed ID: 23064240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
    Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
    Mendell J; Zahir H; Matsushima N; Noveck R; Lee F; Chen S; Zhang G; Shi M
    Am J Cardiovasc Drugs; 2013 Oct; 13(5):331-42. PubMed ID: 23784266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
    Parasrampuria DA; Weilert D; Maa JF; Dishy V; Kochan J; Shi M; Brown KS
    Clin Drug Investig; 2016 Feb; 36(2):127-36. PubMed ID: 26597179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
    Kadokura T; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
    Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):1-9. PubMed ID: 23754514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
    Mendell J; Noveck RJ; Shi M
    Br J Clin Pharmacol; 2013 Apr; 75(4):966-78. PubMed ID: 22924409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
    Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
    Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
    Parasrampuria DA; Truitt KE
    Clin Pharmacokinet; 2016 Jun; 55(6):641-55. PubMed ID: 26620048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edoxaban: a focused review of its clinical pharmacology.
    Lip GY; Agnelli G
    Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
    Yin OQ; Tetsuya K; Miller R
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.
    Mendell J; Tachibana M; Shi M; Kunitada S
    J Clin Pharmacol; 2011 May; 51(5):687-94. PubMed ID: 20534818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
    Zahir H; Matsushima N; Halim AB; He L; Zhang G; Lee F; Worland V; Mendell J
    Thromb Haemost; 2012 Jul; 108(1):166-75. PubMed ID: 22628060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
    Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
    Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
    Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
    Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S67-71. PubMed ID: 8793605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
    Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
    Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
    Duchin K; Duggal A; Atiee GJ; Kidokoro M; Takatani T; Shipitofsky NL; He L; Zhang G; Kakkar T
    Clin Pharmacokinet; 2018 Feb; 57(2):221-228. PubMed ID: 28512699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.